HCA Healthcare, Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: HCA Healthcare, Inc. |
| Ticker: | Ticker: HCA |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
On July 14, 2026, HCA Healthcare issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA Healthcare sharply lowered its full-year 2026 profit guidance, citing an unfavorable shift in the Company’s payer mix, driven by an increase in uninsured volume—primarily due to patients who had lost coverage on health insurance exchanges—which impacted revenue by approximately $400 million in the quarter. The Company lowered its forecast for 2026 earnings to between $28.70 and $30.50 a share and narrowed its revenue target to $77 billion to $79.5 billion from a prior $76.5 billion to $80 billion range. Adjusted earnings before interest, taxes, depreciation and amortization are targeted at between $15.4 billion and $16.1 billion, where HCA Healthcare previously anticipated $15.55 billion to $16.45 billion.
On this news, HCA Healthcare’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.
On this news, HCA Healthcare’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.